Factsheet
Q1 2020/21
---
______
Q1 | Q1 | Q1 | Q1 | ||||||
19/20 | 20/21 | 19/20 | 20/21 | ||||||
Income statement, continuing operations | Growth drivers, continuing operations | ||||||||
Revenue | 220.0 | 243.5 | Organic growth | 2% | 10% | ||||
Gross profit | 132.5 | 136.0 | Volume/mix | na | 5% | ||||
EBITDA b.s.i. | 80.1 | 87.8 | Price | na | 5% | ||||
EBIT b.s.i. | 63.8 | 61.4 | Currencies | 0% | -8% | ||||
Underlying EBIT b.s.i.1 | 63.8 | 63.4 | M&A | 0% | 9% | ||||
EBIT | 63.0 | 55.0 | EUR growth | 2% | 11% | ||||
Net financial items | (2.6) | (6.6) | Organic growth by region, continuing operations | ||||||
Profit for the period | 49.9 | 41.4 | EMEA | -3% | 7% | ||||
Cash flow and investments, continuing operations | NA | 8% | 9% | ||||||
Operating cash flow | 29.9 | 38.8 | LATAM | 9% | 40% | ||||
Investing cash flow | (28.7) | (376.2) | APAC | -2% | -4% | ||||
Free cash flow b.s.i.a.d | 7.5 | (6.9) | Food Cultures & Enzymes | ||||||
M&A | - | (319.0) | Revenue | 166.1 | 165.3 | ||||
Balance sheet, Group | Organic growth | 4% | 8% | ||||||
Total assets | 2,096.8 | 3,228.7 | Volume/mix | 3% | 2% | ||||
Invested capital | 1,816.3 | 2,910.2 | Currencies | -1% | -8% | ||||
Net working capital | 244.1 | 250.4 | M&A | - | - | ||||
Equity | 727.2 | 930.7 | EUR growth | 3% | 0% | ||||
Net interest-bearing debt | 792.8 | 1,706.1 | EBITDA | 64.5 | 65.2 | ||||
Key ratios | EBITDA margin | 38.9% | 39.4% | ||||||
Continuing operations | EBIT | 53.2 | 50.8 | ||||||
Gross margin | 60.2% | 55.9% | EBIT margin, % | 32.1% | 30.7% | ||||
EBITDA margin b.s.i. | 36.4% | 36.1% | ROIC excl. goodwill | 36.7% | 33.4% | ||||
EBIT margin b.s.i | 29.0% | 25.2% | Health & Nutrition | ||||||
Underlying EBIT b.s.i. margin1 | 29.0% | 28.5% | Revenue | 53.9 | 78.2 | ||||
EBIT margin | 28.6% | 22.6% | Organic growth | -4% | 15% | ||||
R&D | 9.3% | 8.6% | Volume/mix | -4% | 13% | ||||
Capex | 10.5% | 22.4% | Currencies | 1% | -8% | ||||
Group | M&A | - | 38% | ||||||
ROIC excl. goodwill | 27.8% | 20.9% | EUR growth | -3% | 45% | ||||
ROIC | 15.7% | 10.4% | EBITDA | 15.6 | 22.6 | ||||
Net debt to EBITDA b.s.i. | 1.9x | 3.8x | EBITDA margin | 28.9% | 28.9% | ||||
EBIT | 10.6 | 10.6 | |||||||
Revenue split by | Revenue split by | ||||||||
business, YTD | region, YTD | EBIT margin, % | 19.6% | 13.6% | |||||
Underlying EBIT1 | 10.6 | 17.3 | |||||||
APAC | Underlying EBIT margin1, % | 19.6% | 22.1% | ||||||
18% | |||||||||
H&N | |||||||||
EMEA | ROIC excl. goodwill | 14.7% | 7.2% | ||||||
32% | |||||||||
37% | |||||||||
LATAM | 1 See Q1 2020/21 company announcement, p. 20, for reconcilation of | ||||||||
13% | underlying margins. |
FC&E
68%
NA 32%
Attachments
- Original document
- Permalink
Disclaimer
Chr. Hansen Holding A/S published this content on 14 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 January 2021 08:45:00 UTC